drugset / Trial / NCT03886493
Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer
Phase 2
Terminated
7 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Regeneron Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single-center, single arm, open-label phase II study evaluating the safety, anti-tumor effect, and immunogenicity of neoadjuvant Dupixent given prior to radical prostatectomy.
Timeline
- Start
- 2019-08-28
- Primary completion
- 2020-10-06
- Completion
- 2020-10-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dupilumab | Monoclonal antibody | 300 mg | Subcutaneous |